Prof. Dr. van Tintelen is principal investigator in the Double Dose Program, which focuses on hypertrophic and dilated cardiomyopathy (HCM and DCM). He is Head of Clinical Genetics at the University Medical Centre, Utrecht (the Netherlands). He is co-founder of the international PLN and ACM mutation databases.